Analysed INSTIL BIO INC (TIL:NASDAQ) News Sources
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
27-03-2026
yahoo.com
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
03-02-2026
fool.com
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
03-02-2026
fool.com
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
06-01-2026
yahoo.com
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
13-11-2025
yahoo.com
Tumor Infiltrating Lymphocytes Therapy Market Research Report 2025-2030: Market Driven by Active R&D from Iovance Biotherapeutics, Juncell Therapeutics, Biosyngen, and Instil Bio
21-10-2025
yahoo.com
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
10-09-2025
yahoo.com
Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company
16-08-2025
yahoo.com
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13-08-2025
yahoo.com
What is the current price of INSTIL BIO INC (TIL:NASDAQ)?
The current price of INSTIL BIO INC (TIL:NASDAQ) is $8.88.
INSTIL BIO INC (TIL:NASDAQ) absolute price change since previous trading day?
The absolute price change of INSTIL BIO INC (TIL:NASDAQ) since the previous trading day is $-0.02.
INSTIL BIO INC (TIL:NASDAQ) percentage price change since previous trading day?
The percentage price change of INSTIL BIO INC (TIL:NASDAQ) since the previous trading day is -0.2247%.
What is the most recent average sentiment score for INSTIL BIO INC (TIL:NASDAQ)?
The most recent average sentiment score for INSTIL BIO INC (TIL:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for INSTIL BIO INC (TIL:NASDAQ)?
The most recent sentiment for INSTIL BIO INC (TIL:NASDAQ) is .
SEC-8K** Filing Available For INSTIL BIO INC (TIL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.